Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04529772
Recruitment Status : Recruiting
First Posted : August 28, 2020
Last Update Posted : January 24, 2022
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 31, 2026
Estimated Study Completion Date : August 31, 2026